GlassScriptPhysician profile
Monica Luthra
NPI 1245692516
$6,543.35
in general payments reported to CMS, 2019-2025
44 companies · $1,177 in 2025
The $1,177 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $867 · 2020: $137 · 2021: $501 · 2022: $1,340 · 2023: $1,212 · 2024: $1,309 · 2025: $1,177.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,698.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,698.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $698.33 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $657.64 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Esperion Therapeutics, INC. | $546.29 | 2022-2025 | Nexletol, Nexlizet |
| Amgen INC. | $481.09 | 2019-2025 | Repatha, Otezla, Krystexxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $467.65 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $440.81 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $287.21 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Pfizer INC. | $262.27 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $215.90 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $185.80 | 2019-2025 | Camzyos, Eliquis |
| Currax Pharmaceuticals LLC | $183.33 | 2022-2025 | Contrave, Onzetra Xsail, Nexletol |
| Amarin Pharma, INC. | $167.54 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $157.74 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $155.71 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $155.21 | 2019-2022 |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $139.37 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbvie INC. | $131.28 | 2022-2024 | |
| Horizon Therapeutics Plc | $126.83 | 2020-2022 | |
| Genzyme Corporation | $124.99 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $119.73 | 2022-2025 | |
| Biogen, INC. | $113.50 | 2021-2022 | |
| Abbott Laboratories | $83.92 | 2023-2025 | Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $78.21 | 2019 | |
| Optinose US, INC. | $55.68 | 2022-2025 | |
| Xeris Pharmaceuticals, INC. | $55.22 | 2021-2023 | Keveyis |
| Ani Pharmaceuticals, INC. | $52.41 | 2025 | Purified Cortrophin Gel |
| Baxter Healthcare | $45.48 | 2023 | Hillrom - Carnation Ambulatory Monitor |
| Shield Therapeutics INC | $37.38 | 2023-2024 | Accrufer |
| Sk Life Science, INC. | $32.82 | 2022 | |
| Acadia Pharmaceuticals INC | $31.41 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $24.25 | 2019 | |
| Vertical Pharmaceuticals, LLC | $22.85 | 2019 | |
| Phathom Pharmaceuticals, INC. | $21.73 | 2025 | Voquezna |
| Idorsia Pharmaceuticals US INC | $20.44 | 2023 | Quviviq |
| Medtronic, INC. | $18.62 | 2023 | Intellis Adaptivestim |
| Viatris Specialty LLC | $18.60 | 2025 | Yupelri |
| Emd Serono, INC. | $18.21 | 2023 | Mavenclad |
| Paratek Pharmaceuticals, INC. | $18.04 | 2025 | Xhance, Nuzyra |
| Daiichi Sankyo INC. | $17.48 | 2023 | Injectafer |
| Amneal Pharmaceuticals LLC | $15.68 | 2022 | |
| Mdd US Operations, LLC | $14.71 | 2022 | |
| Allergan, INC. | $14.18 | 2020 | |
| Ge Healthcare | $14.16 | 2022 | |
| Smith+Nephew, INC. | $13.65 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monica Luthra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.